Compounds for treatment of cancer
US10022356B2 · kind B2 · utility
7Cited by
5References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2014 |
| Grant date | Jul 17, 2018 |
| Priority date | — |
| Expiry date | Mar 5, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/435
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.